Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4740-4748

  Kesteman, Anne Sylvie ^a,b   Ferran, Aude A ^a   Perrin Guyomard, Agnès ^b   Laurentie, Michel ^b   Sanders, Pascal ^b   Toutain, Pierre Louis ^a   Bousquet Mélou, Alain ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b Healthy Pigs Production and Experimentation Section   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MARBOFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; COLONY FORMING UNIT; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG SENSITIVITY; FRACTIONATION; INOCULATION; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LUNG INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; RATS;

EID: 70350292186     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00608-09     Document Type: Article

References (38)

1. Almeida, D., E. Nuermberger, S. Tyagi, W. R. Bishai, and J. Grosset. 2007. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother. 51:4261-4266.
2. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44: 79-86.
3. Andes, D., and W. A. Craig. 2002. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46:1665-1670.
4. Bakker-Woudenberg, I. A., J. Y. de Jong-Hoenderop, and M. F. Michel. 1979. Efficacy of antimicrobial therapy in experimental rat pneumonia: effects of impaired phagocytosis. Infect. Immun. 25:366-375.
5. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
6. Blondeau, J. M., X. Zhao, G. Hansen, and K. Drlica. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:433-438.
7. Burtin, P., F. Mentre, J. van Bree, and J. L. Steimer. 1996. Sparse sampling for assessment of drug exposure in toxicological studies. Eur. J. Drug Metab. Pharmacokinet. 21:105-111.
8. Campion, J. J., P. Chung, P. J. McNamara, W. B. Titlow, and M. E. Evans. 2005. Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:2189-2199.
9. Croisier, D., M. Etienne, E. Bergoin, P. E. Charles, C. Lequeu, L. Piroth, H. Portier, and P. Chavanet. 2004. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob. Agents Chemother. 48:1699-1707.
10. Cui, J., Y. Liu, R. Wang, W. Tong, K. Drlica, and X. Zhao. 2006. The mutant selection window in rabbits infected with Staphylococcus aureus. J. Infect. Dis. 194:1601-1608.
11. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
12. Drlica, K., and X. Zhao. 2007. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44:681-688.
13. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
14. European Agency for the Evaluation of Medicinal Products. 1999. EMEA/MRL/693/99-FINAL. Summary Reports/EPMARs. European Medicines Agency, London, United Kingdom.
15. Ferran, A., V. Dupouy, P. L. Toutain, and A. Bousquet-Melou. 2007. Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin. Antimicrob. Agents Chemother. 51:4163-4166.
16. Ferran, A. A., A. S. Kesteman, P. L. Toutain, and A. Bousquet-Melou. 2009. Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model. Antimicrob. Agents Chemother. 53:3384-3390.
17. Firsov, A. A., I. Y. Lubenko, M. V. Smirnova, E. N. Strukova, and S. H. Zinner. 2008. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob. Agents Chemother. 52:1924-1928.
18. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
19. Hasegawa, T., K. Takagi, and K. Kitaichi. 1999. Effects of bacterial endotoxin on drug pharmacokinetics. Nagoya J. Med. Sci. 62:11-28.
20. Ismail, M., and Y. A. El-Kattan. 2007. Comparative pharmacokinetics of marbofloxacin in healthy and Mannheimia haemolytica infected calves. Res. Vet. Sci. 82:398-404.
21. Khodursky, A. B., E. L. Zechiedrich, and N. R. Cozzarelli. 1995. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc. Natl. Acad. Sci. USA 92:11801-11805.
22. Lavielle, M., and F. Mentre. 2007. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J. Pharmacokinet. Pharmacodyn. 34:229-249.
23. Li, X., X. Zhao, and K. Drlica. 2002. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob. Agents Chemother. 46:522-524.
24. Lipsitch, M., and B. R. Levin. 1997. The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41:363-373.
25. Louie, A., D. L. Brown, W. Liu, R. W. Kulawy, M. R. Deziel, and G. L. Drusano. 2007. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:3988-4000. (Pubitemid 350057798)
26. Mizunaga, S., T. Kamiyama, Y. Fukuda, M. Takahata, and J. Mitsuyama. 2005. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems. J. Antimicrob. Chemother. 56:91-96.
27. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2002. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int. J. Antimicrob. Agents 19:355-358.
28. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607.
29. Peyrou, M., M. Y. Doucet, A. Vrins, D. Concordet, M. Schneider, and A. Bousquet-Melou. 2004. Population pharmacokinetics of marbofloxacin in horses: preliminary analysis. J. Vet. Pharmacol. Ther. 27:283-288.
30. Schneider, M., V. Thomas, B. Boisrame, and J. Deleforge. 1996. Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. J. Vet. Pharmacol. Ther. 19:56-61.
31. Smith, H. J., K. A. Nichol, D. J. Hoban, and G. G. Zhanel. 2003. Stretching the mutant prevention concentration (MPC) beyond its limits. J. Antimicrob. Chemother. 51:1323-1325.
32. Sugino, A., C. L. Peebles, K. N. Kreuzer, and N. R. Cozzarelli. 1977. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Natl. Acad. Sci. USA 74:4767-4771.
33. Toutain, P. L., A. Bousquet-Melou, and M. Martinez. 2007. AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor? J. Antimicrob. Chemother. 60:1185-1188.
34. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
35. Zhao, X. 2003. Clarification of MPC and the mutant selection window concept. J. Antimicrob. Chemother. 52:731-733.
36. Zhao, X., and K. Drlica. 2002. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185:561-565.
37. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3):S147-S156.
38. Zhao, X., and K. Drlica. 2008. A unified anti-mutant dosing strategy. J. Antimicrob. Chemother. 62:434-436.